Search Results - "Ruffilli, B."

290P Metabolomic profiling and response to neoadjuvant therapy (NAT) in early breast cancer (EBC) by Gennari, A., Barberis, E., Martini, V., Gobbato, S., Alsati, R., Ben Ayed, R., Rossi, V., D'Avanzo, F., Ruffilli, B., Malagutti, B., Dodaro, I., Gallarotti, E., Galli, L., Boldorini, R., Gambaro, A., Rampi, A., Branni, C., Manfredi, M.

Get full text

67P High levels of circulating ceramides are associated with poor prognosis in patients with metastatic castration-resistant prostate cancer (mCRPC) by Cattrini, C., Manfredi, M., Barboro, P., Ghirimoldi, M., Mennitto, A., Martini, V., Battioni, A., Le Van, M., Biello, F., Platini, F., Ruffilli, B., Branni, C., Tassone, A., Gobbato, S., Stella, A., Catalano, F., Zanardi, E., Pinato, D.J., Boccardo, F., Gennari, A.

Get full text

Metabolomic profile as a biomarker in early breast cancer patients candidate to neoadjuvant therapy by Martini, V., Ruffilli, B., Di Lascio, S., D’Avanzo, F., Rossi, V., Gobbato, S., Vezzoli, F., Negrini, L., Alsati, R., Ben Ayed, R., Tarantino, G., Guarneri, V., Griguolo, G., Boldorini, R.L., Branni, C., Matera, L., Sala, N., Barberis, E., Manfredi, M., Gennari, A.

Get full text

38P Assessment of lipidomic profile in endocrine receptor-positive (ER+) MBC patients treated with CDK 4/6 inhibitors (CDKi) and endocrine therapy (ET) by Gennari, A., Manfredi, M., Barberis, E., Branni, C., Ben Ayed, R., Gobbato, S., Alsati, R., Stella, A., Rossi, V., Platini, F., Ruffilli, B., Martini, V.

Get full text

26P Lipidic and T cell characterization as prognostic biomarkers for patients with ER+ HER2- metastatic breast cancer (MBC) treated with CDK4/6 inhibitors (CDK4/6i) by Negrini, L., Conte, B., Martini, V., Gobbato, S., Rossi, V., D'Avanzo, F., Ben Ayed, R., Alsati, R., Ruffilli, B., Vezzoli, F., Sala, N., Matera, L., Branni, C., Gennari, J., Barberis, E., Manfredi, M., Gennari, A.

Get full text

Early prediction of endocrine responsiveness in ER+/HER2-negative metastatic breast cancer (MBC): pilot study with 18 F-fluoroestradiol ( 18 F-FES) CT/PET by Gennari, A, Brain, E, De Censi, A, Nanni, O, Wuerstlein, R, Frassoldati, A, Cortes, J, Rossi, V, Palleschi, M, Alberini, J L, Matteucci, F, Piccardo, A, Sacchetti, G, Ilhan, H, D'Avanzo, F, Ruffilli, B, Nardin, S, Monti, M, Puntoni, M, Fontana, V, Boni, L, Harbeck, N

“…F-fluoroestradiol (FES) positron emission tomography (PET)/computed tomography (CT) is considered an accurate diagnostic tool to determine whole-body endocrine…”
Get more information